Ardsley Advisory Partners Has $327,000 Stake in Boston Scientific Co. (BSX)
Ardsley Advisory Partners lessened its position in Boston Scientific Co. (NYSE:BSX) by 50.0% in the second quarter, Holdings Channel reports. The institutional investor owned 10,000 shares of the medical equipment provider’s stock after selling 10,000 shares during the period. Ardsley Advisory Partners’ holdings in Boston Scientific were worth $327,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Rampart Investment Management Company LLC raised its position in shares of Boston Scientific by 230.9% in the first quarter. Rampart Investment Management Company LLC now owns 55,820 shares of the medical equipment provider’s stock valued at $1,525,000 after buying an additional 38,950 shares during the last quarter. Sei Investments Co. raised its position in shares of Boston Scientific by 7.8% in the second quarter. Sei Investments Co. now owns 3,853,853 shares of the medical equipment provider’s stock valued at $126,021,000 after buying an additional 278,777 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Boston Scientific by 63.6% in the second quarter. Nisa Investment Advisors LLC now owns 319,940 shares of the medical equipment provider’s stock valued at $10,462,000 after buying an additional 124,350 shares during the last quarter. Tdam USA Inc. acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $3,758,000. Finally, State Treasurer State of Michigan increased its position in Boston Scientific by 0.9% during the second quarter. State Treasurer State of Michigan now owns 408,496 shares of the medical equipment provider’s stock worth $13,358,000 after purchasing an additional 3,700 shares during the last quarter. 90.91% of the stock is owned by institutional investors and hedge funds.
In other news, EVP David A. Pierce sold 5,000 shares of the stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $32.42, for a total value of $162,100.00. Following the completion of the sale, the executive vice president now owns 29,201 shares of the company’s stock, valued at $946,696.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Michael F. Mahoney sold 116,666 shares of the stock in a transaction on Monday, September 10th. The stock was sold at an average price of $35.88, for a total transaction of $4,185,976.08. Following the completion of the sale, the chairman now directly owns 2,023,104 shares of the company’s stock, valued at approximately $72,588,971.52. The disclosure for this sale can be found here. Insiders sold 175,250 shares of company stock valued at $6,196,995 in the last three months. Company insiders own 0.73% of the company’s stock.
Boston Scientific stock opened at $36.44 on Thursday. Boston Scientific Co. has a 52-week low of $24.54 and a 52-week high of $37.30. The firm has a market capitalization of $49.58 billion, a PE ratio of 28.49, a price-to-earnings-growth ratio of 2.49 and a beta of 0.63. The company has a quick ratio of 0.60, a current ratio of 0.83 and a debt-to-equity ratio of 0.62.
Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 25th. The medical equipment provider reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.07. Boston Scientific had a net margin of 5.48% and a return on equity of 26.35%. The company had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.47 billion. During the same quarter in the prior year, the business earned $0.32 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. research analysts anticipate that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Further Reading: The Role of a Fiduciary and Individual Investors
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.